Loading stock data…
Marsh (MRSH)
$180.52-5.22 (-2.81%)
Pre-Market$180.52+0.00 (+0.00%)· Last close Sep 8
Marsh & McLennan Companies, Inc., a professional services company, provides advisory services and insurance solutions to clients in the areas of risk, strategy, and people worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Marsh & McLennan Companies, Inc. in the Financial Services sector is trading at $180.52 with a market capitalization of $91.5B. Wall Street consensus targets $207.10 (21 analysts), implying a +14.7% move over the next 12 months. The stock is currently 13% below its 52-week high of $207.83, remaining 2.3% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.40B↓ | $7.60B↑ | $6.59B↑ | $6.35B↓ | $6.97B |
| Gross Profit | $3.26B↓ | $3.47B↑ | $2.66B↑ | $2.46B↓ | $3.08B |
| Operating Income | $1.90B↑ | $1.75B↑ | $1.22B↑ | $1.17B↓ | $1.83B |
| Net Income | $1.27B↑ | $1.15B↑ | $821.00M↑ | $747.00M↓ | $1.21B |
Peer Comparison
JPMBACGS
Fundamentals
Marsh & McLennan Companies, Inc., a professional services company, provides advisory services and insurance solutions to clients in the areas of risk, strategy, and people worldwide. The company operates through Risk and Insurance Services, and Consu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$91.46B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.43
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.04%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.21%
Volume
Today's trading volume
2.06M
Recent News
Is Healthcare Services Group (HCSG) Stock Outpacing Its Business Services Peers This Year?
Here is how Healthcare Services (HCSG) and Marsh (MRSH) have performed compared to their sector so far this year.
2 Services Stocks with Promising Prospects and 1 We Ignore
Business services providers play a critical role for enterprises, assisting them with everything from new hardware integrations to consulting and marketing. Furthermore, the demand for their offerings is rising as more clients outsource non-core functions, a trend that has enabled the industry to return 19.8% over the past six months. At the same time, the S&P 500 was up 11.7%.
How Can Healthcare Inflation Fuel Growth for MRSH, UNH & CNC?
Rising employer healthcare costs could boost Marsh's consulting demand and create growth avenues for UnitedHealth and Centene through cost-control solutions.
Marsh & McLennan Companies (MRSH) Launches Cyber Protect And Marsh Re, Is The Stock Still Undervalued?
Cyber Protect launch and Marsh Re rebrand set the scene for Marsh & McLennan Companies stock Marsh & McLennan Companies (MRSH) has drawn investor attention after two recent moves. The company launched Cyber Protect in Asia with Resilience and rolled out a group-wide rebrand that brings Guy Carpenter under the Marsh Re banner. Recent moves such as Cyber Protect and the Marsh Re rebrand come after a mixed period for Marsh & McLennan Companies. The share price is US$187.58 after a recent 7 day...
Marsh & McLennan Companies (MRSH) Stock Looks Reasonable On Fair Value But Rich On Earnings
Marsh & McLennan Companies stock has posted a 28.4% gain over the past five years, yet current valuation checks send mixed signals as the intrinsic value estimate suggests upside while market multiples lean the other way. At the same time, the broader scorecard points to a middle ground rather than a clearly cheap or clearly expensive stock. A 28.4% return over five years indicates Marsh & McLennan Companies has rewarded patient shareholders, which can influence how much of the quality story...